Empfehlungen zum Management der Psoriasisarthritis mit pharmakologischen Therapien – Update der EULAR-Guidelines

Melden Sie sich bitte hier kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Zur Anmeldung

Redaktion: em. o. Univ.-Prof. Dr. Josef Smolen

Klinische Abteilung für Rheumatologie, Universitätsklinik für Innere Medizin III, Medizinische ­Universität Wien


Literatur:

  1. Scotti L, Franchi M, Marchesoni A, Corrao G: Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum 2018
  2. Kerschbaumer A, Smolen JS, Aletaha D: Disease activity assessment in patients with psoriatic arthritis. Best Pract Res Clin Rheumatol 2018; 32(3): 401–414
  3. Smolen JS, Schols M, Braun J, Dougados M, Fitzgerald O, Gladman DD et al.: Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheu Dis 2017
  4. Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS: Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010; 69(8): 1441–1447
  5. Schoels MM, Aletaha D, Alasti F, Smolen JS: Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis 2016; 75(5): 811–818
  6. Gossec L, Smolen JS, Gaujoux-Viala C, Ash Z, Marzo-Ortega H, van der HD et al.: European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012; 71(1): 4–12
  7. Gossec L, Smolen JS, Ramiro S, De Wit M, Cutolo M, Dougados M et al.: European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis 2016; 75(3): 499–510
  8. Gossec L, Baraliakos X, Kerschbaumer A, De Wit M, McInnes I, Dougados M et al.: EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis 2020; 79(6): 700–712
  9. Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ et al.: A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford) 2012; 51(8): 1368–1377
  10. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O’Dwyer JL et al.: Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. Lancet 2015; 386(10012): 2489–2498
  11. Mease PJ, Gladman DD, Collier DH, Ritchlin CT, Helliwell PS, Liu L et al.: Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. Arthritis Rheumatol 2019; 71(7): 1112–1124
  12. Kerschbaumer A, Smolen JS, Aletaha D: Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis Rheumatol 2020; 72(7): 1227–1229
  13. Mease PJ, Smolen JS, Behrens F, Nash P, Liu LS, Li L et al.: A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis 2020; 79(1): 123–131
  14. Reich K, Armstrong AW, Langley RG, Flavin S, Randazzo B, Li S et al.: Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet 2019; 394(10201): 831–839
  15. Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C et al.: A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol 2020; 182(6): 1348–1358
  16. Schoels MM, Aletaha D, Smolen JS: Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. Ann Rheum Dis. 2015 Dec; 74(12): e67
  17. Kerschbaumer A, Smolen JS, Dougados M, de Wit M, Primdahl J, McInnes I, van der Heijde D, Baraliakos X, Falzon L, Gossec L: Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis. 2020 Jun; 79(6): 778–786

FdR 03|2020

Publikationsdatum: 2020-10-06